The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors

Table 3 The diagnostic criteria of VEGF tested and in combination analysis with HE4 and CA125 in ovarian cancer patients

Epithelial ovarian cancer	Diagnostic criteria (%)	VEGF	HE4	CA125	VEGF + HE4	VEGF + CA125	HE4+ CA125	VEGF + HE4 + CA125
I stage	Sensitivity	44	44	40	76	72	72	84
	Specificity	94	94	92	88	88	88	82
	PV-PR	78	78	71	76	75	75	70
	PV-NR	77	77	75	88	86	86	91
II stage	Sensitivity	48	28	64	64	76	80	96
	Specificity	94	94	92	88	88	88	82
	PV-PR	75	70	80	72	76	76	72
	PV-NR	74	72	83	83	88	89	97
III stage	Sensitivity	72	68	80	88	92	88	96
	Specificity	94	94	92	88	88	88	82
	PV-PR	85	85	83	78	79	78	72
	PV-NR	87	85	90	93	95	93	97
IV stage	Sensitivity	40	80	84	88	92	92	96
	Specificity	94	94	92	88	88	88	82
	PV-PR	76	86	84	78	79	95	72
	PV-NR	75	85	92	93	95	79	97
Total group	Sensitivity	48	55	67	81	83	83	93
	Specificity	94	94	92	88	88	88	82
	PV-PR	94	94	94	93	93	93	91
	PV-NR	47	51	58	69	72	72	85
*Serous epithelial*	Sensitivity	46	70	64	81	77	88	94
	Specificity	94	94	92	88	88	88	82
	PV-PR	89	88	92	88	87	88	95
	PV-NR	71	74	71	81	78	88	93
*Endometrioid epithelial*	Sensitivity	50	36	69	71	91	80	95
	Specificity	94	94	92	88	88	88	82
	PV-PR	88	80	91	84	87	86	83
	PV-NR	67	61	77	77	93	83	95

ISSN: 1757-2215